The Effect of GeriLact on Non-Alcoholic Fatty Liver Disease by صدرکبیر, محمد et al.
 
82 
 
JKMU 
Journal of Kerman University of Medical Sciences, 2020; 27 (1): 82-90 
 
The Effect of GeriLact on Non-Alcoholic Fatty Liver Disease 
Mohammad Sadrkabir, M.D.
1
, Shirin Jahed, M.D.
2
, Zahra Sadeghi, M.D. 
3
, Khatereh Isazadeh, M.D. 
4
 
 
1- Assistant Professor, Department of Internal Medicine, Islamic Azad University, Tabriz Branch, Tabriz, Iran 
2- Assistant Professor, Department of Internal Medicine, School of Medicine, Ardabil University of Medical Science, Ardabil, Iran 
3- School of Medicine, Ardabil University of Medical Science, Ardabil, Iran (Corresponding author; E-mail: z.sadeghi@arums.ac.ir) 
4- Associate Professor, Department of Community Medicine, School of Medicine, Ardabil University of Medical Science, Ardabil, Iran  
Received: 12 May, 2019  Accepted: 7 January, 2020 
 
 
ARTICLE INFO 
 
Original Article 
Non-alcoholic fatty liver disease 
ALT 
Lipid profile 
Probiotics 
 Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver 
disease which is correlated with overweight, obesity, and insulin resistance. Recently, the use 
of probiotics has been suggested for these patients as they have considerable outcomes. The 
aim of the present study is to evaluate the effect of GeriLact on patients with NAFLD. 
 In this randomized clinical trial, 61 patients with NAFLD were recruited and 
randomly assigned to groups receiving GeriLact, 500 mg, twice per day, or placebo (with the 
same dose) for sixty days. Weight, body mass index (BMI), lipid profile, fasting blood sugar 
(FBS), Alanine aminotransferase (ALT), Aspartate Aminotransferase (AST), and 
sonographic grading were evaluated before and at the end of the study.  
 In the GeriLact group, there was a significant decrease in ALT (p=0.002) and AST 
(p<0.001) levels, while the placebo group showed a significant decrease only in ALT level 
(p=0.01). There was a significant decrease in cholesterol levels in the intervention group 
compared to the placebo group (p=0.01), but there were no significant changes in FBS, 
triglycerides, LDL, and HDL levels between the two groups. The fatty liver grade was 
improved by 63.6% in the intervention group and by 46.4% in the placebo group.  
 The results showed that probiotics caused significant improvement in ALT, 
AST, and cholesterol levels but had no effects on FBS, triglycerides, low-density lipoprotein 
(LDL), and high-density lipoprotein (HDL). Overall, treatment with GeriLact was found to 
be effective, safe, with low cost and well-tolerated in the long term use by the patients.  
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Materials and Methods 
Study type and area 
Participants  
 
Inclusion and exclusion criteria 
 
Data collection procedure  
The Effect of GeriLact on Non-Alcoholic … Sadrkabir, et al 
84 
 
Laboratory Measurements  
 
Statistical Analysis 
Figure 1. Study design 
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Results 
Table 1. Baseline demographic and anthropometric data of the NAFLD patients  
Groups 
Variables 
Gerilact Placebo 
p-value 
n % n % 
Sex 
male 22 66.7 18 64.3 
0.84 
female  11 33.3 10 35.7 
Age Mean ± SD 43.26±11.42 43.72±10.76 0.88 
Weight 
Mean ± SD 
Before 88.15±14.6 90.75±10.1 0.43 
After 86.42±13.8 86.7±10.3 0.93 
BMI 
Mean ± SD 
Before 31.87±5.4 30.83±4.6 0.44 
After 31.53±5.83 29.1±3.76 0.09 
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Table 2. Mean level of liver enzymes and lipid profile lipid among all patients in two groups  
Groups 
Variables 
Gerilact Placebo p-value 
AST 
Mean ± SD 
Pretreatment 28.8±9.6 29.8±21.8 0.82 
Post-treatment 23.84±7.5 27.8±19.1 0.28 
ALT 
Mean ± SD 
Pretreatment 48.93±33.64 49.2±35.3 0.97 
Post-treatment 31.4±12.7 42.9±29.6 0.04 
FBS 
Mean ± SD 
Pretreatment 92.4±12.3 92.4±8.1 0.99 
Post-treatment 90.6±9.4 90±10.1 0.78 
TG 
Mean ± SD 
Pretreatment 188.6±62.6 226.7±108.3 0.09 
Post-treatment 189.6±109.3 200.4±90 0.68 
CHOL 
Mean ± SD 
Pretreatment 189.2±32.6 190.4±45.1 0.9 
Post-treatment 173.8±37.9 200.7±55.5 0.03 
LDL 
Mean ± SD 
Pretreatment 105.43±25.8 106.1±25.1 0.92 
Post-treatment 103.9±29.3 111.03±24.8 0.32 
HDL 
Mean ± SD 
Pretreatment 45±12.9 40.2±8.3 0.11 
Post-treatment 41.5±7.4 39.7±10.6 0.44 
 
Table 3. The difference mean of anthropometric indices among the patients in two groups  
Groups 
Variables 
Gerilact Placebo p-value 
Weight -2.81±2.8 -3.7±3.3 0.48 
BMI  ̀ -2.25±2.14 -3.3±3.1 0.38 
AST -14.9±21.3 55.3±3.9 0.02 
ALT -21.1±37.42 -4.9±40.32 0.01 
FBS -1.24±8.72 -2.5±9.9 0.58 
TG -0.11±33.9 -6.2±26.1 0.74 
CHOL -5.7±25.6 5.4±17.1 0.01 
LDL 1.46±26.3 6.18±20.6 0.13 
HDL -2.14±17.7 2.1±24.2 0.15 
 
Table 4. Changes in the grade of fatty liver in two groups by sex 
Grade of fatty liver 
Gerilact Placebo 
p-value 
n % n % 
Male 
Improved 16 72.7 10 55.6 
0.35 Non-change 6 27.3 7 38.9 
Progressed 0 0 1 5.6 
Female 
Improved 5 45.5 3 30 
0.38 Non-change 5 45.5 6 60 
Progressed 5 9 1 10 
Total 
Improved 21 63.6 13 46.4 
0.33 Non-change 11 33.3 14 50 
Progressed 1 3 1 3.6 
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